AMARILLO, Texas, Aug. 13, 2025 /PRNewswire/ -- Maxor Specialty Pharmacy, a VytlOne company, was selected by Insmed to be a limited distribution provider of Brinsupri^™. Brinsupri is a dipeptidyl peptidase 1 (DPP1) inhibitor indicated for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult and pediatric patients 12 years of age and older.

Brinsupri is the latest addition to a growing number of limited distribution products available through VytlOne.

"We are excited to partner with Insmed for the launch of Brinsupri, the first FDA-approved medication for the treatment of bronchiectasis," said Joel Wright, President, VytlOne Pharmacy Services. "This milestone underscores our commitment to the rare disease community, and we are honored to play a role in the improvement of the lives of our bronchiectasis patients."

About VytlOne

VytlOne is the nation's only independent, fully integrated total pharmacy solutions partner. A leader in rare and orphan disease management, Maxor Specialty Pharmacy (which will be re-branded as of VytlOne Specialty Pharmacy as of January 1, 2026) integrates sophisticated clinical management strategies with a personalized high-touch approach to patient engagement, and holds licenses in all 50 states, as well as accreditations from URAC, ACHC, and The Joint Commission.

VytlOne supports and enables our partners to drive sustainable revenue growth while achieving optimal outcomes for their patients living with rare disease.

Learn more at www.vytlone.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/vytlone-announces-new-partnership-with-insmed-302529214.html

SOURCE VytlOne